Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905123 | 0.95 | ALDH1A1 (0.33) | TGFBR1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL905070 | 0.91 | TGFBR1 (0.34) | TGFBR1 | |
| SCHEMBL15132321 | 0.81 | TGFBR1 (0.36) | TGFBR1 | |
| SCHEMBL905121 | 0.81 | TGFBR1 (0.36) | TGFBR1POLB | |
| SCHEMBL905081 | 0.77 | ZDHHC20 (0.44) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30956649 | 0.76 | ALDH1A1 (0.33) | TGFBR1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL905092 | 0.75 | TGFBR1 (0.32) | TGFBR1 | |
| SCHEMBL10000902 | 0.75 | TGFBR1 (0.35) | TGFBR1 | |
| SCHEMBL28346305 | 0.73 | KDM4E (0.37) | TGFBR1ALDH1A1MEN1KMT2A | |
| SCHEMBL25557372 | 0.73 | ANPEP (0.41) | TGFBR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9204652-B2 | Antibacterial agent, substrate surface treatment method using the same, antibacterial agent composition, and substrate surface treatment method using the same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2622960-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | Central Glass Company, Limited (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| WO-2012043619-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | セントラル硝子株式会社 (JP) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | SEM1, CD81, VMA21 | TGFBR1 1915/4885ALDH1A1 1200/4885POLB 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.